Technical Analysis for ATNX - Athenex, Inc.

Grade Last Price % Change Price Change
grade D 16.3 -1.98% -0.33
ATNX closed down 1.98 percent on Friday, April 20, 2018, on 37 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. Its advance stalled at its 200 day moving average, an important long-term support / resistance line. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical ATNX trend table...

Date Alert Name Type % Chg
Apr 20 200 DMA Resistance Bearish 0.00%
Apr 20 Fell Below 50 DMA Bearish 0.00%
Apr 20 Expansion Pivot Sell Setup Bearish Swing Setup 0.00%
Apr 20 Stochastic Reached Oversold Weakness 0.00%
Apr 20 Down 3 Days in a Row Weakness 0.00%
Apr 20 Oversold Stochastic Weakness 0.00%
Apr 19 Downside 200 DMA Break Bearish -1.98%
Apr 19 Oversold Stochastic Weakness -1.98%
Apr 18 Outside Day Range Expansion -5.23%
Apr 17 Narrow Range Bar Range Contraction -5.78%

Older signals for ATNX ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Athenex, Inc. is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company's technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics. The Company offers Oraxol, an oral formulation of paclitaxel; Orateacan, an oral formulation of Irinotecan; Oradoxel, an oral formulation of Docetaxel, and an oral formulation of Topotecan for the treatment of various types of cancers. Its Src Kinase Inhibitors include KX-01 (KX2-391) and KX-02 (KX2-361) oncology drug candidates. The Company's Symptom Therapeutics include CQ-01, which is used for the treatment of burn pruritus and scars; CQ-R1, which is used for the treatment of an irradiation-induced dermatitis, and an intranasal Granisetron used for the treatment of chemotherapy-induced nausea/vomiting.
Is ATNX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 20.79
52 Week Low 11.21
Average Volume 328,180
200-Day Moving Average 16.6896
50-Day Moving Average 16.5355
20-Day Moving Average 17.1418
10-Day Moving Average 17.183
Average True Range 0.6433
ADX 22.78
+DI 12.32
-DI 30.08
Chandelier Exit (Long, 3 ATRs ) 16.0701
Chandelier Exit (Short, 3 ATRs ) 16.3299
Upper Bollinger Band 18.3887
Lower Bollinger Band 15.8949
Percent B (%b) 0.16
BandWidth 14.548064
MACD Line 0.0752
MACD Signal Line 0.23
MACD Histogram -0.1548
Fundamentals Value
Market Cap 930.13 Million
Num Shares 57.1 Million
EPS -3.47
Price-to-Earnings (P/E) Ratio -4.70
Price-to-Sales 47.88
Price-to-Book 7.97
PEG Ratio 0.98
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.44
Resistance 3 (R3) 17.51 17.20 17.25
Resistance 2 (R2) 17.20 16.91 17.17 17.19
Resistance 1 (R1) 16.75 16.73 16.60 16.68 17.12
Pivot Point 16.44 16.44 16.36 16.41 16.44
Support 1 (S1) 15.99 16.15 15.84 15.92 15.48
Support 2 (S2) 15.68 15.97 15.65 15.41
Support 3 (S3) 15.23 15.68 15.35
Support 4 (S4) 15.16